In this issue of Blood, Eisfeld and colleagues present strong evidence that miR-3151 and the host gene BAALC (brain and acute leukemia, cytoplasmic) concomitantly affect the outcome of patients with cytogenetically normal acute myeloid leukemia (CN-AML) by influencing significant signaling pathways.